A pseudotype vesicular stomatitis virus containing Hantaan virus envelope glycoproteins G1 and G2 as an alternative to hantavirus vaccine in mice

被引：24

作者：

Lee, BH ^{[1
]}

Yoshimatsu, K ^{[1
]}

Araki, K ^{[1
]}

Okumura, M ^{[1
]}

Nakamura, I ^{[1
]}

Arikawa, J ^{[1
]}

机构：

[1] Hokkaido Univ, Grad Sch Med, Inst Anim Expt, Kita Ku, Sapporo, Hokkaido 0608638, Japan

来源：

VACCINE | 2006年 / 24卷 / 15期

关键词：

envelope; hantavirus; pseudotype;

D O I：

10.1016/j.vaccine.2005.12.040

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

We examined whether a vesicular stomatitis virus (VSV) pseudotype bearing the hantavirus envelope glycoproteins (GPs) G1 and G2 (VSV Delta G*HTN) could be used as a safe and effective alternative to native hantavirus. Mice were immunized with purified particles of VSV Delta G*HTN. After the second immunization, all mice produced anti-GP antibody as detected in ELISA and a neutralization test. After the third immunization, the mice were challenged with Hantaan virus. Neither anti-NP antibody production nor Hantaan virus-specific CD8 T-cell reactions were detected in these mice. The present study demonstrated the potential of using a pseudotype VSV system as a tool for developing a hantavirus vaccine. (c) 2005 Elsevier Ltd. All rights reserved.

引用

页码：2928 / 2934

页数：7

共 32 条

[1] Hantavirus-specific CD8+-T-cell responses in newborn mice persistently infected with Hantaan virus
Araki, K
Yoshimatsu, K
Lee, BH
Kariwa, H
Takashima, I
Arikawa, J
[J]. JOURNAL OF VIROLOGY, 2003, 77 (15) : 8408 - 8417
[2] Truncated hantavirus nucleocapsid proteins for serotyping Hantaan, Seoul, and Dobrava hantavirus infections
Araki, K
Yoshimatsu, K
Ogino, M
Ebihara, H
Lundkvist, Å
Kariwa, H
Takashima, I
Arikawa, J
[J]. JOURNAL OF CLINICAL MICROBIOLOGY, 2001, 39 (07) : 2397 - 2404
[3] CHARACTERIZATION OF HANTAAN VIRUS ENVELOPE GLYCOPROTEIN ANTIGENIC DETERMINANTS DEFINED BY MONOCLONAL-ANTIBODIES
ARIKAWA, J
SCHMALJOHN, AL
DALRYMPLE, JM
SCHMALJOHN, CS
[J]. JOURNAL OF GENERAL VIROLOGY, 1989, 70 : 615 - 624
[4] CROSS-REACTIVE IMMUNITY AMONG DIFFERENT SEROTYPES OF VIRUS CAUSING HEMORRHAGIC-FEVER WITH RENAL SYNDROME
ASADA, H
BALACHANDRA, K
TAMURA, M
KONDO, K
YAMANISHI, K
[J]. JOURNAL OF GENERAL VIROLOGY, 1989, 70 : 819 - 825
[5] Hepatitis C virus envelope glycoproteins and potential for vaccine development
Beyene, A
Basu, A
Meyer, K
Ray, R
[J]. VOX SANGUINIS, 2002, 83 : 27 - 32
[6] CRYSTALLIZATION OF THE FAB FROM A HUMAN MONOCLONAL-ANTIBODY AGAINST GP-41 OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-I
CASALE, E
WENISCH, E
HE, XM
RIGHETTI, PG
SNYDER, RS
JUNGBAUER, A
TAUER, C
RUKER, F
CARTER, DC
[J]. JOURNAL OF MOLECULAR BIOLOGY, 1990, 216 (03) : 511 - 512
[7] TECHNIQUES FOR HEMAGGLUTINATION AND HEMAGGLUTINATION-INHIBITION WITH ARTHROPOD-BORNE VIRUSES
CLARKE, DH
CASALS, J
[J]. AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 1958, 7 (05) : 561 - 573
[8] *HANT VACC DEP, 1996, B WORLD HEALTH ORGAN, V74, P336
[9] ANTI-HBS RESPONSES TO VACCINATION WITH A HUMAN HEPATITIS-B VACCINE MADE BY RECOMBINANT-DNA TECHNOLOGY IN YEAST
HOLLINGER, FB
TROISI, CL
PEPE, PE
[J]. JOURNAL OF INFECTIOUS DISEASES, 1986, 153 (01) : 156 - 159
[10] DNA vaccination with Hantavirus M segment elicits neutralizing antibodies and protects against Seoul virus infection
Hooper, JW
Kamrud, KI
Elgh, F
Custer, D
Schmaljohn, CS
[J]. VIROLOGY, 1999, 255 (02) : 269 - 278

← 1 2 3 4 →